SCHEMBL30765705

SCHEMBL30765705

CSc1ncc(NCc2ccc3oc4ccccc4c3c2)c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
LMNA P02545 4/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 3/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCRTR1 O43613 3/20 0.35
HCRTR2 O43614 3/20 0.35
PDE10A Q9Y233 1/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765947 0.88 LMNA (0.40) ALDH1A1KDM4ELMNANPSR1RXFP1
SCHEMBL30765891 0.86 GAA (0.40) ALDH1A1KDM4ELMNANPSR1MAPT
SCHEMBL30765931 0.85 ALDH1A1 (0.37) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765941 0.85 ALDH1A1 (0.37) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765777 0.84 HCRTR1 (0.40) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765836 0.83 KDM4E (0.36) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765833 0.83 JAK2 (0.38) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765944 0.81 ALDH1A1 (0.37) ALDH1A1KDM4ELMNAJAK2JAK1
SCHEMBL30765948 0.81 LMNA (0.39) LMNANPSR1RXFP1
SCHEMBL30765939 0.81 LMNA (0.35) ALDH1A1KDM4ELMNAJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed